Abstract
Von Willebrand factor (VWF) and coagulation factor VIII (FVIII) circulate as a complex in plasma and have a major role in the hemostatic system. VWF has a dual role in hemostasis. It promotes platelet adhesion by anchoring the platelets to the subendothelial matrix of damaged vessels and it protects FVIII from proteolytic degradation. Moreover, VWF is an acute phase protein that has multiple roles in vascular inflammation and is massively secreted from Weibel-Palade bodies upon endothelial cell activation. Activated FVIII on the other hand, together with coagulation factor IX forms the tenase complex, an essential feature of the propagation phase of coagulation on the surface of activated platelets. VWF deficiency, either quantitative or qualitative, results in von Willebrand disease (VWD), the most common bleeding disorder. The deficiency of FVIII is responsible for Hemophilia A, an X-linked bleeding disorder. Here, we provide an overview on the role of the VWF-FVIII interaction in vascular physiology.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Albanez S, Ogiwara K, Michels A, Hopman W, Grabell J, James P, Lillicrap D (2016) Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms. J Thromb Haemost 14(5):953â963. https://doi.org/10.1111/jth.13294
Alevriadou BR, Moake JL, Turner NA, Ruggeri ZM, Folie BJ, Phillips MD, Schreiber AB, Hrinda ME, McIntire LV (1993) Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 81(5):1263â1276
Andrews RK, Berndt MC (2013) The GPIb-IX-V complex. In: Michelson AD (ed) Platelets, 3rd edn. Elsevier, London, pp 195â213
Arneth B (2019) Coevolution of the coagulation and immune systems. Inflamm Res 68(2):117â123. https://doi.org/10.1007/s00011-018-01210-y
Baaij M, van Galen KP, Urbanus RT, Nigten J, Eikenboom JH, Schutgens RE (2015) First report of inhibitory von Willebrand factor alloantibodies in type 2B von Willebrand disease. Br J Haematol 171(3):424â427. https://doi.org/10.1111/bjh.13395
Babich V, Meli A, Knipe L, Dempster JE, Skehel P, Hannah MJ, Carter T (2008) Selective release of molecules from Weibel-Palade bodies during a lingering kiss. Blood 111(11):5282â5290. https://doi.org/10.1182/blood-2007-09-113746
Baglia FA, Badellino KO, Li CQ, Lopez JA, Walsh PN (2002) Factor XI binding to the platelet glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin. J Biol Chem 277(3):1662â1668. https://doi.org/10.1074/jbc.M108319200
Bahou WF, Ginsburg D, Sikkink R, Litwiller R, Fass DN (1989) A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide. J Clin Invest 84 (1):56â61. https://doi.org/10.1172/jci114169
Bajaj SP, Schmidt AE, Mathur A, Padmanabhan K, Zhong D, Mastri M, Fay PJ (2001) Factor IXa:factor VIIIa interaction. helix 330â338 of factor ixa interacts with residues 558-565 and spatially adjacent regions of the a2 subunit of factor VIIIa. J Biol Chem 276 (19):16302-16309. https://doi.org/10.1074/jbc.m011680200
Baker J, Griggs RK, Falati S, Poole AW (2004) GPIb potentiates GPVI-induced responses in human platelets. Platelets 15(4):207â214. https://doi.org/10.1080/09537100410001701010
Batlle J, Lopez-Fernandez MF, Fraga EL, Trillo AR, Perez-Rodriguez MA (2009) Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease. Blood Coagul Fibrinolysis 20(2):89â100. https://doi.org/10.1097/MBC.0b013e3283254570
Bennett JS, Vilaire G (1979) Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 64(5):1393â1401. https://doi.org/10.1172/JCI109597
Bledzka K, Pesho MM, Ma Y, Plow EE (2013) Integrin αIIbβ3. In: Michelson AD (ed) Platelets, 3rd edn. Elsevier, London, pp 233â248
Bohm M, Betz C, Miesbach W, Krause M, von Auer C, Geiger H, Scharrer I (2005) The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol 129(5):644â652. https://doi.org/10.1111/j.1365-2141.2005.05512.x
Bontempo FA, Lewis JH, Gorenc TJ, Spero JA, Ragni MV, Scott JP, Starzl TE (1987) Liver transplantation in hemophilia A. Blood 69(6):1721â1724
Bonthron D, Orr EC, Mitsock LM, Ginsburg D, Handin RI, Orkin SH (1986) Nucleotide sequence of pre-pro-von Willebrand factor cDNA. Nucleic Acids Res 14(17):7125â7127. https://doi.org/10.1093/nar/14.17.7125
Borchiellini A, Fijnvandraat K, ten Cate JW, Pajkrt D, van Deventer SJ, Pasterkamp G, Meijer-Huizinga F, Zwart-Huinink L, Voorberg J, van Mourik JA (1996) Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 88(8):2951â2958
Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, Rothschild C, Berntorp E, Henriet C, Tellier Z, Bridey F, Mannucci PM (2007) Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 5(6):1115â1124. https://doi.org/10.1111/j.1538-7836.2007.02562.x
Bovenschen N, Rijken DC, Havekes LM, van Vlijmen BJ, Mertens K (2005) The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost 3(6):1257â1265. https://doi.org/10.1111/j.1538-7836.2005.01389.x
Bowman M, Hopman WM, Rapson D, Lillicrap D, James P (2010) The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost 8(1):213â216. https://doi.org/10.1111/j.1538-7836.2009.03661.x
Bradford HN, Pixley RA, Colman RW (2000) Human factor XII binding to the glycoprotein Ib-IX-V complex inhibits thrombin-induced platelet aggregation. J Biol Chem 275(30):22756â22763. https://doi.org/10.1074/jbc.M002591200
Brehelin M, Zachary D, Hoffmann JA (1978) A comparative ultrastructural study of blood cells from nine insect orders. Cell Tissue Res 195(1):45â57. https://doi.org/10.1007/bf00233676
Brehm MA (2017) Von Willebrand factor processing. Hamostaseologie 37(1):59â72. https://doi.org/10.5482/HAMO-16-06-0018
Budde U, Metzner HJ, Muller HG (2006) Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease. Semin Thromb Hemost 32(6):626â635. https://doi.org/10.1055/s-2006-949668
Canis K, McKinnon TA, Nowak A, Panico M, Morris HR, Laffan M, Dell A (2010) The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs. J Thromb Haemost 8(1):137â145. https://doi.org/10.1111/j.1538-7836.2009.03665.x
Canis K, McKinnon TA, Nowak A, Haslam SM, Panico M, Morris HR, Laffan MA, Dell A (2012) Mapping the N-glycome of human von Willebrand factor. Biochem J 447(2):217â228. https://doi.org/10.1042/BJ20120810
Casari C, Du V, Wu YP, Kauskot A, de Groot PG, Christophe OD, Denis CV, de Laat B, Lenting PJ (2013a) Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia. Blood 122(16):2893â2902. https://doi.org/10.1182/blood-2013-03-493312
Casari C, Lenting PJ, Wohner N, Christophe OD, Denis CV (2013b) Clearance of von Willebrand factor. J Thromb Haemost 11(Suppl 1):202â211. https://doi.org/10.1111/jth.12226
Castro-Nunez L, Dienava-Verdoold I, Herczenik E, Mertens K, Meijer AB (2012) Shear stress is required for the endocytic uptake of the factor VIII-von Willebrand factor complex by macrophages. J Thromb Haemost 10(9):1929â1937. https://doi.org/10.1111/j.1538-7836.2012.04860.x
Chauhan AK, Kisucka J, Lamb CB, Bergmeier W, Wagner DD (2007) von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins. Blood 109(6):2424â2429. https://doi.org/10.1182/blood-2006-06-028241
Chen J, Chung DW (2018) Inflammation, von Willebrand factor, and ADAMTS13. Blood 132(2):141â147. https://doi.org/10.1182/blood-2018-02-769000
Coppola R, Mari D, Lattuada A, Franceschi C (2003) Von Willebrand factor in Italian centenarians. Haematologica 88(1):39â43
Dagil L, Troelsen KS, Bolt G, Thim L, Wu B, Zhao X, Tuddenham EGD, Nielsen TE, Tanner DA, Faber JH, Breinholt J, Rasmussen JE, Hansen DF (2019) Interaction Between the a3 Region of Factor VIII and the TILâEâ Domains of the von Willebrand Factor. Biophys J 117(3):479â489. https://doi.org/10.1016/j.bpj.2019.07.007
Dasgupta S, Repesse Y, Bayry J, Navarrete AM, Wootla B, Delignat S, Irinopoulou T, Kamate C, Saint-Remy JM, Jacquemin M, Lenting PJ, Borel-Derlon A, Kaveri SV, Lacroix-Desmazes S (2007) VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 109(2):610â612. https://doi.org/10.1182/blood-2006-05-022756
De Marco L, Girolami A, Zimmerman TS, Ruggeri ZM (1986) von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest 77 (4):1272â1277. https://doi.org/10.1172/jci112430
Denis C, Methia N, Frenette PS, Rayburn H, Ullman-Cullere M, Hynes RO, Wagner DD (1998) A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A 95(16):9524â9529. https://doi.org/10.1073/pnas.95.16.9524
Denorme F, Kraft P, Pareyn I, Drechsler C, Deckmyn H, Vanhoorelbeke K, Kleinschnitz C, De Meyer SF (2017) Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease. PLoS ONE 12(6):e0179258. https://doi.org/10.1371/journal.pone.0179258
Dhanesha N, Prakash P, Doddapattar P, Khanna I, Pollpeter MJ, Nayak MK, Staber JM, Chauhan AK (2016) Endothelial Cell-Derived von Willebrand Factor Is the Major Determinant That Mediates von Willebrand Factor-Dependent Acute Ischemic Stroke by Promoting Postischemic Thrombo-Inflammation. Arterioscler Thromb Vasc Biol 36(9):1829â1837. https://doi.org/10.1161/ATVBAHA.116.307660
Do H, Healey JF, Waller EK, Lollar P (1999) Expression of factor VIII by murine liver sinusoidal endothelial cells. J Biol Chem 274(28):19587â19592. https://doi.org/10.1074/jbc.274.28.19587
Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, Lopez JA (2002) ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100(12):4033â4039. https://doi.org/10.1182/blood-2002-05-1401
Durrant TN, van den Bosch MT, Hers I (2017) Integrin alphaIIbbeta3 outside-in signaling. Blood 130(14):1607â1619. https://doi.org/10.1182/blood-2017-03-773614
Ellies LG, Ditto D, Levy GG, Wahrenbrock M, Ginsburg D, Varki A, Le DT, Marth JD (2002) Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. Proc Natl Acad Sci U S A 99(15):10042â10047. https://doi.org/10.1073/pnas.142005099
Everett LA, Cleuren AC, Khoriaty RN, Ginsburg D (2014) Murine coagulation factor VIII is synthesized in endothelial cells. Blood 123(24):3697â3705. https://doi.org/10.1182/blood-2014-02-554501
Fahs SA, Hille MT, Shi Q, Weiler H, Montgomery RR (2014) A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood 123(24):3706â3713. https://doi.org/10.1182/blood-2014-02-555151
Federici AB (2008) The use of desmopressin in von Willebrand disease: the experience of the first 30Â years (1977-2007). Haemophilia 14(Suppl 1):5â14. https://doi.org/10.1111/j.1365-2516.2007.01610.x
Federici AB, Bader R, Pagani S, Colibretti ML, De Marco L, Mannucci PM (1989) Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size. Br J Haematol 73(1):93â99. https://doi.org/10.1111/j.1365-2141.1989.tb00226.x
Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, Lethagen S, Nitu I, Ludwig G, Hilbert L, Mannucci PM (2004) Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 103(6):2032â2038. https://doi.org/10.1182/blood-2003-06-2072
Fernandez MF, Ginsberg MH, Ruggeri ZM, Batlle FJ, Zimmerman TS (1982) Multimeric structure of platelet factor VIII/von Willebrand factor: the presence of larger multimers and their reassociation with thrombin-stimulated platelets. Blood 60(5):1132â1138
Ferraro F, Kriston-Vizi J, Metcalf DJ, Martin-Martin B, Freeman J, Burden JJ, Westmoreland D, Dyer CE, Knight AE, Ketteler R, Cutler DF (2014) A two-tier Golgi-based control of organelle size underpins the functional plasticity of endothelial cells. Dev Cell 29(3):292â304. https://doi.org/10.1016/j.devcel.2014.03.021
Floyd CN, Ferro A (2012) The platelet fibrinogen receptor: from megakaryocyte to the mortuary. JRSM Cardiovasc Dis 1 (2). https://doi.org/10.1258/cvd.2012.012007
Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS (1987) A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 262(18):8443â8446
Foster PA, Fulcher CA, Houghten RA, Zimmerman TS (1988) An immunogenic region within residues Val1670-Glu1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor. J Biol Chem 263(11):5230â5234
Franchini M (2010) Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better. Blood Transfus 8(4):292â296. https://doi.org/10.2450/2010.0067-10
Frankel DS, Meigs JB, Massaro JM, Wilson PW, OâDonnell CJ, DâAgostino RB, Tofler GH (2008) Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the framingham offspring study. Circulation 118(24):2533â2539. https://doi.org/10.1161/CIRCULATIONAHA.108.792986
Fressinaud E, Girma JP, Sadler JE, Baumgartner HR, Meyer D (1990) Synthetic RGDS-containing peptides of von Willebrand factor inhibit platelet adhesion to collagen. Thromb Haemost 64(4):589â593
Fujimura Y, Holland LZ, Ruggeri ZM, Zimmerman TS (1987) The von willebrand factor domain-mediating botrocetin-induced binding to glycoprotein IB lies between Val449 and Lys728. Blood 70(4):985â988
Furlan M, Lammle B (1999) von Willebrand factor in thrombotic thrombocytopenic purpura. Thromb Haemost 82(2):592â600
Gharagozlou S, Sharifian RA, Khoshnoodi J, Karimi K, Milani M, Okita DK, Shokri F, Conti-Fine BM (2009) Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains. Thromb Haemost 101(5):834â839
Gibbins JM, Okuma M, Farndale R, Barnes M, Watson SP (1997) Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain. FEBS Lett 413(2):255â259. https://doi.org/10.1016/s0014-5793(97)00926-5
Giblin JP, Hewlett LJ, Hannah MJ (2008) Basal secretion of von Willebrand factor from human endothelial cells. Blood 112(4):957â964. https://doi.org/10.1182/blood-2007-12-130740
Giddings JC, Brookes LR, Piovella F, Bloom AL (1982) Immunohistological comparison of platelet factor 4 (PF4), fibronectin (Fn) and factor VIII related antigen (VIIIR:Ag) in human platelet granules. Br J Haematol 52(1):79â88. https://doi.org/10.1111/j.1365-2141.1982.tb03863.x
Ginsburg D, Handin RI, Bonthron DT, Donlon TA, Bruns GA, Latt SA, Orkin SH (1985) Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 228(4706):1401â1406. https://doi.org/10.1126/science.3874428
Gitschier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH, Vehar GA, Capon DJ, Lawn RM (1984) Characterization of the human factor VIII gene. Nature 312(5992):326â330. https://doi.org/10.1038/312326a0
Goto S, Ikeda Y, Saldivar E, Ruggeri ZM (1998) Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest 101(2):479â486. https://doi.org/10.1172/JCI973
Goudemand J, Mazurier C, Marey A, Caron C, Coupez B, Mizon P, Goudemand M (1992) Clinical and biological evaluation in von Willebrandâs disease of a von Willebrand factor concentrate with low factor VIII activity. Br J Haematol 80(2):214â221. https://doi.org/10.1111/j.1365-2141.1992.tb08903.x
Grant KR (2015) Fish Hematology and Associated Disorders. Clin Lab Med 35(3):681â701. https://doi.org/10.1016/j.cll.2015.05.015
Grassle S, Huck V, Pappelbaum KI, Gorzelanny C, Aponte-Santamaria C, Baldauf C, Grater F, Schneppenheim R, Obser T, Schneider SW (2014) von Willebrand factor directly interacts with DNA from neutrophil extracellular traps. Arterioscler Thromb Vasc Biol 34(7):1382â1389. https://doi.org/10.1161/ATVBAHA.113.303016
Graw J, Brackmann HH, Oldenburg J, Schneppenheim R, Spannagl M, Schwaab R (2005) Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet 6(6):488â501. https://doi.org/10.1038/nrg1617
Grewal PK, Uchiyama S, Ditto D, Varki N, Le DT, Nizet V, Marth JD (2008) The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med 14(6):648â655. https://doi.org/10.1038/nm1760
Groot E, de Groot PG, Fijnheer R, Lenting PJ (2007) The presence of active von Willebrand factor under various pathological conditions. Curr Opin Hematol 14(3):284â289. https://doi.org/10.1097/MOH.0b013e3280dce531
Guan J, Guillot PV, Aird WC (1999) Characterization of the mouse von Willebrand factor promoter. Blood 94(10):3405â3412
Haberichter SL, Merricks EP, Fahs SA, Christopherson PA, Nichols TC, Montgomery RR (2005) Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells. Blood 105(1):145â152. https://doi.org/10.1182/blood-2004-02-0464
Haberichter SL, Shi Q, Montgomery RR (2006) Regulated release of VWF and FVIII and the biologic implications. Pediatr Blood Cancer 46(5):547â553. https://doi.org/10.1002/pbc.20658
Hillgruber C, Steingraber AK, Poppelmann B, Denis CV, Ware J, Vestweber D, Nieswandt B, Schneider SW, Goerge T (2014) Blocking von Willebrand factor for treatment of cutaneous inflammation. J Invest Dermatol 134(1):77â86. https://doi.org/10.1038/jid.2013.292
Hollestelle MJ, Thinnes T, Crain K, Stiko A, Kruijt JK, van Berkel TJ, Loskutoff DJ, van Mourik JA (2001) Tissue distribution of factor VIII gene expression in vivoâa closer look. Thromb Haemost 86(3):855â861
Hollestelle MJ, Donkor C, Mantey EA, Chakravorty SJ, Craig A, Akoto AO, OâDonnell J, van Mourik JA, Bunn J (2006) von Willebrand factor propeptide in malaria: evidence of acute endothelial cell activation. Br J Haematol 133(5):562â569. https://doi.org/10.1111/j.1365-2141.2006.06067.x
Huang J, Roth R, Heuser JE, Sadler JE (2009) Integrin alpha(v)beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress. Blood 113(7):1589â1597. https://doi.org/10.1182/blood-2008-05-158584
Hyseni A, Kemperman H, de Lange DW, Kesecioglu J, de Groot PG, Roest M (2014) Active von Willebrand factor predicts 28-day mortality in patients with systemic inflammatory response syndrome. Blood 123(14):2153â2156. https://doi.org/10.1182/blood-2013-08-508093
Ishihara J, Ishihara A, Starke RD, Peghaire CR, Smith KE, McKinnon TAJ, Tabata Y, Sasaki K, White MJV, Fukunaga K, Laffan MA, Lutolf MP, Randi AM, Hubbell JA (2019) The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing. Blood 133(24):2559â2569. https://doi.org/10.1182/blood.2019000510
Jackel S, Kiouptsi K, Lillich M, Hendrikx T, Khandagale A, Kollar B, Hormann N, Reiss C, Subramaniam S, Wilms E, Ebner K, Bruhl MV, Rausch P, Baines JF, Haberichter S, Lammle B, Binder CJ, Jurk K, Ruggeri ZM, Massberg S, Walter U, Ruf W, Reinhardt C (2017) Gut microbiota regulate hepatic von Willebrand factor synthesis and arterial thrombus formation via Toll-like receptor-2. Blood 130(4):542â553. https://doi.org/10.1182/blood-2016-11-754416
Jacquemin M, Neyrinck A, Hermanns MI, Lavendâhomme R, Rega F, Saint-Remy JM, Peerlinck K, Van Raemdonck D, Kirkpatrick CJ (2006) FVIII production by human lung microvascular endothelial cells. Blood 108(2):515â517. https://doi.org/10.1182/blood-2005-11-4571
James PD, Lillicrap D, Mannucci PM (2013) Alloantibodies in von Willebrand disease. Blood 122(5):636â640. https://doi.org/10.1182/blood-2012-10-462085
Jorieux S, Gaucher C, Pietu G, Cherel G, Meyer D, Mazurier C (1994) Fine epitope mapping of monoclonal antibodies to the NH2-terminal part of von Willebrand factor (vWF) by using recombinant and synthetic peptides: interest for the localization of the factor VIII binding domain. Br J Haematol 87(1):113â118. https://doi.org/10.1111/j.1365-2141.1994.tb04879.x
Joseph K, Nakazawa Y, Bahou WF, Ghebrehiwet B, Kaplan AP (1999) Platelet glycoprotein Ib: a zinc-dependent binding protein for the heavy chain of high-molecular-weight kininogen. Mol Med 5(8):555â563
Jurk K, Clemetson KJ, de Groot PG, Brodde MF, Steiner M, Savion N, Varon D, Sixma JJ, Van Aken H, Kehrel BE (2003) Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. FASEB J 17(11):1490â1492. https://doi.org/10.1096/fj.02-0830fje
Kalagara T, Moutsis T, Yang Y, Pappelbaum KI, Farken A, Cladder-Micus L, Vidal YSS, John A, Bauer AT, Moerschbacher BM, Schneider SW, Gorzelanny C (2018) The endothelial glycocalyx anchors von Willebrand factor fibers to the vascular endothelium. Blood Adv 2(18):2347â2357. https://doi.org/10.1182/bloodadvances.2017013995
Kallas A, Talpsep T (2001) von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 7(4):375â380. https://doi.org/10.1046/j.1365-2516.2001.00530.x
Kamphuisen PW, Eikenboom JC, Rosendaal FR, Koster T, Blann AD, Vos HL, Bertina RM (2001) High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br J Haematol 115(1):156â158. https://doi.org/10.1046/j.1365-2141.2001.03089.x
Kaufman RJ, Wasley LC, Dorner AJ (1988) Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 263(13):6352â6362
Kawai Y, Montgomery RR (1987) Endothelial cell processing of von Willebrand proteins. Ann N Y Acad Sci 509:60â70. https://doi.org/10.1111/j.1749-6632.1987.tb30984.x
Kiouptsi K, Grill A, Mann A, Dohrmann M, Lillich M, Jackel S, Malinarich F, Formes H, Manukyan D, Subramaniam S, Khandagale A, Karwot C, Thal SC, Bosmann M, Scharrer I, Jurk K, Reinhardt C (2017) Mice deficient in the anti-haemophilic coagulation factor VIII show increased von Willebrand factor plasma levels. PLoS ONE 12(8):e0183590. https://doi.org/10.1371/journal.pone.0183590
Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345(8943):152â155. https://doi.org/10.1016/s0140-6736(95)90166-3
Kowalska MA, Tuszynski GP (1993) Interaction of thrombospondin with platelet glycoproteins GPIa-IIa and GPIIb-IIIa. Biochem J 295(Pt 3):725â730. https://doi.org/10.1042/bj2950725
Lai J, Hough C, Tarrant J, Lillicrap D (2017) Biological considerations of plasma-derived and recombinant factor VIII immunogenicity. Blood 129(24):3147â3154. https://doi.org/10.1182/blood-2016-11-750885
Lapan KA, Fay PJ (1997) Localization of a factor X interactive site in the A1 subunit of factor VIIIa. J Biol Chem 272(4):2082â2088. https://doi.org/10.1074/jbc.272.4.2082
Leebeek FW, Eikenboom JC (2016) Von Willebrandâs Disease. N Engl J Med 375(21):2067â2080. https://doi.org/10.1056/NEJMra1601561
Legaz ME, Schmer G, Counts RB, Davie EW (1973) Isolation and characterization of human Factor VIII (antihemophilic factor). J Biol Chem 248(11):3946â3955
Lenting PJ, van de Loo JW, Donath MJ, van Mourik JA, Mertens K (1996) The sequence Glu 1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem 271(4):1935â1940. https://doi.org/10.1074/jbc.271.4.1935
Lenting PJ, Neels JG, van den Berg BM, Clijsters PP, Meijerman DW, Pannekoek H, van Mourik JA, Mertens K, van Zonneveld AJ (1999) The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J Biol Chem 274(34):23734â23739. https://doi.org/10.1074/jbc.274.34.23734
Lenting PJ, Christophe OD, Denis CV (2015) von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood 125(13):2019â2028. https://doi.org/10.1182/blood-2014-06-528406
Lethagen S, Carlson M, Hillarp A (2004) A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia 10(3):243â249. https://doi.org/10.1111/j.1365-2516.2004.00893.x
Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413(6855):488â494. https://doi.org/10.1038/35097008
Leyte A, van Schijndel HB, Niehrs C, Huttner WB, Verbeet MP, Mertens K, van Mourik JA (1991) Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 266(2):740â746
Lippok S, Kolsek K, Lof A, Eggert D, Vanderlinden W, Muller JP, Konig G, Obser T, Rohrs K, Schneppenheim S, Budde U, Baldauf C, Aponte-Santamaria C, Grater F, Schneppenheim R, Radler JO, Brehm MA (2016) von Willebrand factor is dimerized by protein disulfide isomerase. Blood 127(9):1183â1191. https://doi.org/10.1182/blood-2015-04-641902
Liu ML, Shen BW, Nakaya S, Pratt KP, Fujikawa K, Davie EW, Stoddard BL, Thompson AR (2000) Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure. Blood 96 (3):979â987
Lollar P, Hill-Eubanks DC, Parker CG (1988) Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 263(21):10451â10455
Lynch DC, Zimmerman TS, Collins CJ, Brown M, Morin MJ, Ling EH, Livingston DM (1985) Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method. Cell 41(1):49â56. https://doi.org/10.1016/0092-8674(85)90060-1
Mannucci PM, Canciani MT, Rota L, Donovan BS (1981) Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrandâs disease. Br J Haematol 47(2):283â293. https://doi.org/10.1111/j.1365-2141.1981.tb02789.x
Mannucci PM, Kempton C, Millar C, Romond E, Shapiro A, Birschmann I, Ragni MV, Gill JC, Yee TT, Klamroth R, Wong WY, Chapman M, Engl W, Turecek PL, Suiter TM, Ewenstein BM (2013) Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood 122(5):648â657. https://doi.org/10.1182/blood-2013-01-479527
Marchioro TL, Hougie C, Ragde H, Epstein RB, Thomas ED (1969) Hemophilia: role of organ homografts. Science 163(3863):188â190. https://doi.org/10.1126/science.163.3863.188
Marti T, Rosselet SJ, Titani K, Walsh KA (1987) Identification of disulfide-bridged substructures within human von Willebrand factor. Biochemistry 26(25):8099â8109. https://doi.org/10.1021/bi00399a013
Marx I, Christophe OD, Lenting PJ, Rupin A, Vallez MO, Verbeuren TJ, Denis CV (2008) Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood 112(3):603â609. https://doi.org/10.1182/blood-2008-02-142943
Matsui T, Titani K, Mizuochi T (1992) Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. J Biol Chem 267 (13):8723â8731
Mayadas TN, Wagner DD (1989) In vitro multimerization of von Willebrand factor is triggered by low pH. Importance of the propolypeptide and free sulfhydryls. J Biol Chem 264 (23):13497â13503
McGrath RT, van den Biggelaar M, Byrne B, OâSullivan JM, Rawley O, OâKennedy R, Voorberg J, Preston RJ, OâDonnell JS (2013) Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis. Blood 122(25):4107â4110. https://doi.org/10.1182/blood-2013-04-496851
Methia N, Andre P, Denis CV, Economopoulos M, Wagner DD (2001) Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood 98(5):1424â1428. https://doi.org/10.1182/blood.v98.5.1424
Mohri H, Ohkubo T (1991) How vitronectin binds to activated glycoprotein IIb-IIIa complex and its function in platelet aggregation. Am J Clin Pathol 96(5):605â609. https://doi.org/10.1093/ajcp/96.5.605
Montgomery RR, Gill JC (2000) Interactions between von Willebrand factor and Factor VIII: where did they first meet. J Pediatr Hematol Oncol 22(3):269â275. https://doi.org/10.1097/00043426-200005000-00017
Moreau A, Lacroix-Desmazes S, Stieltjes N, Saenko E, Kaveri SV, DâOiron R, Sultan Y, Scandella D, Kazatchkine MD (2000) Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG. Blood 95(11):3435â3441
Muntean W, Leschnik B (1989) Factor VIII influences binding of factor IX and factor X to intact human platelets. Thromb Res 55(5):537â548. https://doi.org/10.1016/0049-3848(89)90386-1
Nesheim M, Pittman DD, Giles AR, Fass DN, Wang JH, Slonosky D, Kaufman RJ (1991) The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets. J Biol Chem 266(27):17815â17820
Nogami K, Shima M, Hosokawa K, Suzuki T, Koide T, Saenko EL, Scandella D, Shibata M, Kamisue S, Tanaka I, Yoshioka A (1999) Role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem 274(43):31000â31007. https://doi.org/10.1074/jbc.274.43.31000
Nogami K, Shima M, Hosokawa K, Nagata M, Koide T, Saenko EL, Tanaka I, Shibata M, Yoshioka A (2000) Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689. J Biol Chem 275(33):25774â25780. https://doi.org/10.1074/jbc.M002007200
OâSullivan JM, Preston RJS, Robson T, OâDonnell JS (2018) Emerging Roles for von Willebrand Factor in Cancer Cell Biology. Semin Thromb Hemost 44(2):159â166. https://doi.org/10.1055/s-0037-1607352
Pan J, Dinh TT, Rajaraman A, Lee M, Scholz A, Czupalla CJ, Kiefel H, Zhu L, Xia L, Morser J, Jiang H, Santambrogio L, Butcher EC (2016) Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo. Blood 128(1):104â109. https://doi.org/10.1182/blood-2015-12-684688
Pappelbaum KI, Gorzelanny C, Grassle S, Suckau J, Laschke MW, Bischoff M, Bauer C, Schorpp-Kistner M, Weidenmaier C, Schneppenheim R, Obser T, Sinha B, Schneider SW (2013) Ultralarge von Willebrand factor fibers mediate luminal Staphylococcus aureus adhesion to an intact endothelial cell layer under shear stress. Circulation 128(1):50â59. https://doi.org/10.1161/CIRCULATIONAHA.113.002008
Paulus P, Jennewein C, Zacharowski K (2011) Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis? Biomarkers 16(Suppl 1):S11âS21. https://doi.org/10.3109/1354750X.2011.587893
Pegon JN, Kurdi M, Casari C, Odouard S, Denis CV, Christophe OD, Lenting PJ (2012) Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5. Haematologica 97(12):1855â1863. https://doi.org/10.3324/haematol.2012.063297
Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EG, Kemball-Cook G (1997) A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood 89(7):2413â2421
Peyvandi F, Kouides P, Turecek PL, Dow E, Berntorp E (2019a) Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor. Blood Rev 38:100572. https://doi.org/10.1016/j.blre.2019.04.001
Peyvandi F, Mamaev A, Wang JD, Stasyshyn O, Timofeeva M, Curry N, Cid AR, Yee TT, Kavakli K, Castaman G, Sytkowski A (2019b) Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery. J Thromb Haemost 17(1):52â62. https://doi.org/10.1111/jth.14313
Pfistershammer K, Stockl J, Siekmann J, Turecek PL, Schwarz HP, Reipert BM (2006) Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells. Thromb Haemost 96(3):309â316. https://doi.org/10.1160/TH05-11-0729
Pinsky DJ, Naka Y, Liao H, Oz MC, Wagner DD, Mayadas TN, Johnson RC, Hynes RO, Heath M, Lawson CA, Stern DM (1996) Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. J Clin Invest 97 (2):493â500. https://doi.org/10.1172/jci118440
Pottinger BE, Read RC, Paleolog EM, Higgins PG, Pearson JD (1989) von Willebrand factor is an acute phase reactant in man. Thromb Res 53(4):387â394. https://doi.org/10.1016/0049-3848(89)90317-4
Poulter NS, Pollitt AY, Owen DM, Gardiner EE, Andrews RK, Shimizu H, Ishikawa D, Bihan D, Farndale RW, Moroi M, Watson SP, Jung SM (2017) Clustering of glycoprotein VI (GPVI) dimers upon adhesion to collagen as a mechanism to regulate GPVI signaling in platelets. J Thromb Haemost 15(3):549â564. https://doi.org/10.1111/jth.13613
Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL (1999) Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 402 (6760):439â442. https://doi.org/10.1038/46601
Preston AE, Barr A (1964) The Plasma Concentration of Factor Viii in the Normal Population. Ii. The Effects of Age, Sex and Blood Group. Br J Haematol 10:238â245. https://doi.org/10.1111/j.1365-2141.1964.tb00698.x
Przeradzka MA, Meems H, van der Zwaan C, Ebberink E, van den Biggelaar M, Mertens K, Meijer AB (2018) The Dâ domain of von Willebrand factor requires the presence of the D3 domain for optimal factor VIII binding. Biochem J 475(17):2819â2830. https://doi.org/10.1042/BCJ20180431
Randi AM, Smith KE, Castaman G (2018) von Willebrand factor regulation of blood vessel formation. Blood 132(2):132â140. https://doi.org/10.1182/blood-2018-01-769018
Rastegarlari G, Pegon JN, Casari C, Odouard S, Navarrete AM, Saint-Lu N, van Vlijmen BJ, Legendre P, Christophe OD, Denis CV, Lenting PJ (2012) Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood 119(9):2126â2134. https://doi.org/10.1182/blood-2011-08-373605
Ratnoff OD (1987) The evolution of hemostatic mechanisms. Perspect Biol Med 31(1):4â33. https://doi.org/10.1353/pbm.1987.0003
Reinhart K, Bayer O, Brunkhorst F, Meisner M (2002) Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 30(5 Suppl):S302âS312. https://doi.org/10.1097/00003246-200205001-00021
Reininger AJ, Heijnen HF, Schumann H, Specht HM, Schramm W, Ruggeri ZM (2006) Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood 107(9):3537â3545. https://doi.org/10.1182/blood-2005-02-0618
Rivera J, Lozano ML, Navarro-Nunez L, Vicente V (2009) Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica 94(5):700â711. https://doi.org/10.3324/haematol.2008.003178
Rojo Pulido I, Nightingale TD, Darchen F, Seabra MC, Cutler DF, Gerke V (2011) Myosin Va acts in concert with Rab27a and MyRIP to regulate acute von-Willebrand factor release from endothelial cells. Traffic 12(10):1371â1382. https://doi.org/10.1111/j.1600-0854.2011.01248.x
Romani de Wit T, Rondaij MG, Hordijk PL, Voorberg J, van Mourik JA (2003) Real-time imaging of the dynamics and secretory behavior of Weibel-Palade bodies. Arterioscler Thromb Vasc Biol 23(5):755â761. https://doi.org/10.1161/01.ATV.0000069847.72001.E8
Romo GM, Dong JF, Schade AJ, Gardiner EE, Kansas GS, Li CQ, McIntire LV, Berndt MC, Lopez JA (1999) The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med 190(6):803â814. https://doi.org/10.1084/jem.190.6.803
Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J (2006) Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol 26(5):1002â1007. https://doi.org/10.1161/01.ATV.0000209501.56852.6c
Rosenberg JB, Foster PA, Kaufman RJ, Vokac EA, Moussalli M, Kroner PA, Montgomery RR (1998) Intracellular trafficking of factor VIII to von Willebrand factor storage granules. J Clin Invest 101(3):613â624. https://doi.org/10.1172/JCI1250
Rosenberg JB, Greengard JS, Montgomery RR (2000) Genetic induction of a releasable pool of factor VIII in human endothelial cells. Arterioscler Thromb Vasc Biol 20(12):2689â2695. https://doi.org/10.1161/01.atv.20.12.2689
Ruggeri ZM, Mendolicchio GL (2015) Interaction of von Willebrand factor with platelets and the vessel wall. Hamostaseologie 35(3):211â224. https://doi.org/10.5482/HAMO-14-12-0081
Ruggeri ZM, Zimmerman TS (1980) Variant von Willebrandâs disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest 65(6):1318â1325. https://doi.org/10.1172/JCI109795
Ruggeri ZM, Orje JN, Habermann R, Federici AB, Reininger AJ (2006) Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood 108(6):1903â1910. https://doi.org/10.1182/blood-2006-04-011551
Sadler JE, Shelton-Inloes BB, Sorace JM, Harlan JM, Titani K, Davie EW (1985) Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proc Natl Acad Sci U S A 82(19):6394â6398. https://doi.org/10.1073/pnas.82.19.6394
Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB, Party Working on von Willebrand Disease C (2006) Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 4(10):2103â2114. https://doi.org/10.1111/j.1538-7836.2006.02146.x
Saenko EL, Scandella D (1997) The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor. J Biol Chem 272(29):18007â18014. https://doi.org/10.1074/jbc.272.29.18007
Saenko EL, Yakhyaev AV, Mikhailenko I, Strickland DK, Sarafanov AG (1999) Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J Biol Chem 274(53):37685â37692. https://doi.org/10.1074/jbc.274.53.37685
Sakariassen KS, Orning L, Turitto VT (2015) The impact of blood shear rate on arterial thrombus formation. Future Sci OA 1 (4):FSO30. https://doi.org/10.4155/fso.15.28
Salvagno GL, Astermark J, Ekman M, Franchini M, Guidi GC, Lippi G, Poli G, Berntorp E (2007) Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Haemophilia 13(1):51â56. https://doi.org/10.1111/j.1365-2516.2006.01400.x
Savage B, Saldivar E, Ruggeri ZM (1996) Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 84(2):289â297. https://doi.org/10.1016/s0092-8674(00)80983-6
Savage B, Almus-Jacobs F, Ruggeri ZM (1998) Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 94(5):657â666. https://doi.org/10.1016/s0092-8674(00)81607-4
Schneider SW, Nuschele S, Wixforth A, Gorzelanny C, Alexander-Katz A, Netz RR, Schneider MF (2007) Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci U S A 104(19):7899â7903. https://doi.org/10.1073/pnas.0608422104
Schwarz HP, Lenting PJ, Binder B, Mihaly J, Denis C, Dorner F, Turecek PL (2000) Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice. Blood 95(5):1703â1708
Senis YA, Richardson M, Tinlin S, Maurice DH, Giles AR (1996) Changes in the pattern of distribution of von Willebrand factor in rat aortic endothelial cells following thrombin generation in vivo. Br J Haematol 93(1):195â203. https://doi.org/10.1046/j.1365-2141.1996.4661005.x
Shahani T, Covens K, Lavendâhomme R, Jazouli N, Sokal E, Peerlinck K, Jacquemin M (2014) Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII. J Thromb Haemost 12(1):36â42. https://doi.org/10.1111/jth.12412
Shi Q, Wilcox DA, Fahs SA, Kroner PA, Montgomery RR (2003) Expression of human factor VIII under control of the platelet-specific alphaIIb promoter in megakaryocytic cell line as well as storage together with VWF. Mol Genet Metab 79(1):25â33
Shi Q, Fahs SA, Kuether EL, Cooley BC, Weiler H, Montgomery RR (2010) Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A. Blood 116(16):3049â3057. https://doi.org/10.1182/blood-2010-03-272419
Simon DI, Chen Z, Xu H, Li CQ, Dong J, McIntire LV, Ballantyne CM, Zhang L, Furman MI, Berndt MC, Lopez JA (2000) Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 192(2):193â204. https://doi.org/10.1084/jem.192.2.193
Sivaraman B, Latour RA (2011) Delineating the roles of the GPIIb/IIIa and GP-Ib-IX-V platelet receptors in mediating platelet adhesion to adsorbed fibrinogen and albumin. Biomaterials 32(23):5365â5370. https://doi.org/10.1016/j.biomaterials.2011.04.011
Souto JC, Almasy L, Muniz-Diaz E, Soria JM, Borrell M, Bayen L, Mateo J, Madoz P, Stone W, Blangero J, Fontcuberta J (2000) Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol 20(8):2024â2028. https://doi.org/10.1161/01.atv.20.8.2024
Springer TA (2011) Biology and physics of von Willebrand factor concatamers. J Thromb Haemost 9(Suppl 1):130â143. https://doi.org/10.1111/j.1538-7836.2011.04320.x
Starke RD, Ferraro F, Paschalaki KE, Dryden NH, McKinnon TA, Sutton RE, Payne EM, Haskard DO, Hughes AD, Cutler DF, Laffan MA, Randi AM (2011) Endothelial von Willebrand factor regulates angiogenesis. Blood 117(3):1071â1080. https://doi.org/10.1182/blood-2010-01-264507
Suo J, Linke B, Meyer dos Santos S, Pierre S, Stegner D, Zhang DD, Denis CV, Geisslinger G, Nieswandt B, Scholich K (2014) Neutrophils mediate edema formation but not mechanical allodynia during zymosan-induced inflammation. J Leukoc Biol 96(1):133â142. https://doi.org/10.1189/jlb.3A1213-628R
Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K (1996) Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 76(5):749â754
Swystun LL, Lai JD, Notley C, Georgescu I, Paine AS, Mewburn J, Nesbitt K, Schledzewski K, Geraud C, Kzhyshkowska J, Goerdt S, Hopman W, Montgomery RR, James PD, Lillicrap D (2018) The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity. J Clin Invest 128(9):4057â4073. https://doi.org/10.1172/JCI96400
Swystun LL, Notley C, Georgescu I, Lai JD, Nesbitt K, James PD, Lillicrap D (2019) The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner. J Thromb Haemost 17(4):681â694. https://doi.org/10.1111/jth.14404
Tagliavacca L, Moon N, Dunham WR, Kaufman RJ (1997) Identification and functional requirement of Cu(I) and its ligands within coagulation factor VIII. J Biol Chem 272(43):27428â27434. https://doi.org/10.1074/jbc.272.43.27428
Thompson AR (2003) Structure and function of the factor VIII gene and protein. Semin Thromb Hemost 29(1):11â22. https://doi.org/10.1055/s-2003-37935
Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, Ashida K, Walsh KA, Chopek MW, Sadler JE, Fujikawa K (1986) Amino acid sequence of human von Willebrand factor. Biochemistry 25(11):3171â3184. https://doi.org/10.1021/bi00359a015
Trabold K, Makhoul S, Gambaryan S, van Ryn J, Walter U, Jurk K (2019) The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIbalpha-Mediated Platelet Aggregation. Thromb Haemost 119(6):916â929. https://doi.org/10.1055/s-0039-1685139
Tracy RP, Arnold AM, Ettinger W, Fried L, Meilahn E, Savage P (1999) The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study. Arterioscler Thromb Vasc Biol 19(7):1776â1783. https://doi.org/10.1161/01.atv.19.7.1776
Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339(22):1585â1594. https://doi.org/10.1056/NEJM199811263392203
Tuddenham EG, Lane RS, Rotblat F, Johnson AJ, Snape TJ, Middleton S, Kernoff PB (1982) Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrandâs disease. Br J Haematol 52(2):259â267. https://doi.org/10.1111/j.1365-2141.1982.tb03888.x
Turecek PL, Mitterer A, Matthiessen HP, Gritsch H, Varadi K, Siekmann J, Schnecker K, Plaimauer B, Kaliwoda M, Purtscher M, Woehrer W, Mundt W, Muchitsch EM, Suiter T, Ewenstein B, Ehrlich HJ, Schwarz HP (2009) Development of a plasma- and albumin-free recombinant von Willebrand factor. Hamostaseologie 29(Suppl 1):S32âS38
Turner NA, Moake JL (2015) Factor VIII Is Synthesized in Human Endothelial Cells, Packaged in Weibel-Palade Bodies and Secreted Bound to ULVWF Strings. PLoS ONE 10(10):e0140740. https://doi.org/10.1371/journal.pone.0140740
Urisono Y, Sakata A, Matsui H, Kasuda S, Ono S, Yoshimoto K, Nishio K, Sho M, Akiyama M, Miyata T, Okuchi K, Nishimura S, Sugimoto M (2018) Von Willebrand Factor Aggravates Hepatic Ischemia-Reperfusion Injury by Promoting Neutrophil Recruitment in Mice. Thromb Haemost 118(4):700â708. https://doi.org/10.1055/s-0038-1636529
van Bladel ER, Tuinenburg A, Roest M, de Groot PG, Schutgens RE (2014) Factor VIII concentrate infusion in patients with haemophilia results in decreased von Willebrand factor and ADAMTS-13 activity. Haemophilia 20(1):92â98. https://doi.org/10.1111/hae.12266
van Mourik JA, Boertjes R, Huisveld IA, Fijnvandraat K, Pajkrt D, van Genderen PJ, Fijnheer R (1999) von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation. Blood 94(1):179â185
van Schooten CJ, Shahbazi S, Groot E, Oortwijn BD, van den Berg HM, Denis CV, Lenting PJ (2008) Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 112(5):1704â1712. https://doi.org/10.1182/blood-2008-01-133181
Verbruggen B, Giles A, Samis J, Verbeek K, Mensink E, Novakova I (2001) The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors. Thromb Haemost 86(6):1435â1439
Verhenne S, Denorme F, Libbrecht S, Vandenbulcke A, Pareyn I, Deckmyn H, Lambrecht A, Nieswandt B, Kleinschnitz C, Vanhoorelbeke K, De Meyer SF (2015) Platelet-derived VWF is not essential for normal thrombosis and hemostasis but fosters ischemic stroke injury in mice. Blood 126(14):1715â1722. https://doi.org/10.1182/blood-2015-03-632901
Verweij CL, Hofker M, Quadt R, Briet E, Pannekoek H (1985) RFLP for a human von Willebrand factor (vWF) cDNA clone, pvWF1100. Nucleic Acids Res 13(22):8289. https://doi.org/10.1093/nar/13.22.8289
Vischer UM, Ingerslev J, Wollheim CB, Mestries JC, Tsakiris DA, Haefeli WE, Kruithof EK (1997) Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) Levels. Thromb Haemost 77(2):387â393
Vlot AJ, Koppelman SJ, van den Berg MH, Bouma BN, Sixma JJ (1995) The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood 85(11):3150â3157
Vlot AJ, Koppelman SJ, Meijers JC, Dama C, van den Berg HM, Bouma BN, Sixma JJ, Willems GM (1996) Kinetics of factor VIII-von Willebrand factor association. Blood 87(5):1809â1816
Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, Haan E, Kruitwagen CL, Sixma JJ, van den Berg HM (2000) The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost 83(1):65â69
Wagner DD (1990) Cell biology of von Willebrand factor. Annu Rev Cell Biol 6:217â246. https://doi.org/10.1146/annurev.cb.06.110190.001245
Walker FJ, Scandella D, Fay PJ (1990) Identification of the binding site for activated protein C on the light chain of factors V and VIII. J Biol Chem 265(3):1484â1489
Ward CM, Tetaz TJ, Andrews RK, Berndt MC (1997) Binding of the von Willebrand factor A1 domain to histone. Thromb Res 86(6):469â477. https://doi.org/10.1016/s0049-3848(97)00096-0
Weeterings C, de Groot PG, Adelmeijer J, Lisman T (2008) The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface. Blood 112(8):3227â3233. https://doi.org/10.1182/blood-2008-02-139113
Weisel JW, Nagaswami C, Vilaire G, Bennett JS (1992) Examination of the platelet membrane glycoprotein IIb-IIIa complex and its interaction with fibrinogen and other ligands by electron microscopy. J Biol Chem 267(23):16637â16643
Weiss HJ, Sussman, II, Hoyer LW (1977) Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrandâs disease. J Clin Invest 60 (2):390â404. https://doi.org/10.1172/jci108788
White GC, 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, Factor V, Factor IXS (2001) Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 85 (3):560
Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JC, de Maat MP, Leebeek FW, Breteler MM (2010) High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke 41(10):2151â2156. https://doi.org/10.1161/STROKEAHA.110.586289
Wion KL, Kelly D, Summerfield JA, Tuddenham EG, Lawn RM (1985) Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 317(6039):726â729. https://doi.org/10.1038/317726a0
Wise RJ, Dorner AJ, Krane M, Pittman DD, Kaufman RJ (1991) The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J Biol Chem 266(32):21948â21955
Yuan L, Chan GC, Beeler D, Janes L, Spokes KC, Dharaneeswaran H, Mojiri A, Adams WJ, Sciuto T, Garcia-Cardena G, Molema G, Kang PM, Jahroudi N, Marsden PA, Dvorak A, Regan ER, Aird WC (2016) A role of stochastic phenotype switching in generating mosaic endothelial cell heterogeneity. Nat Commun 7:10160. https://doi.org/10.1038/ncomms10160
Zhou YF, Springer TA (2014) Highly reinforced structure of a C-terminal dimerization domain in von Willebrand factor. Blood 123(12):1785â1793. https://doi.org/10.1182/blood-2013-11-523639
Zhou YF, Eng ET, Zhu J, Lu C, Walz T, Springer TA (2012) Sequence and structure relationships within von Willebrand factor. Blood 120(2):449â458. https://doi.org/10.1182/blood-2012-01-405134
Zhu X, Cao Y, Wei L, Cai P, Xu H, Luo H, Bai X, Lu L, Liu JR, Fan W, Zhao BQ (2016) von Willebrand factor contributes to poor outcome in a mouse model of intracerebral haemorrhage. Sci Rep 6:35901. https://doi.org/10.1038/srep35901
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Kiouptsi, K., Reinhardt, C. (2020). Physiological Roles of the von Willebrand Factor-Factor VIII Interaction. In: Hoeger, U., Harris, J. (eds) Vertebrate and Invertebrate Respiratory Proteins, Lipoproteins and other Body Fluid Proteins. Subcellular Biochemistry, vol 94. Springer, Cham. https://doi.org/10.1007/978-3-030-41769-7_18
Download citation
DOI: https://doi.org/10.1007/978-3-030-41769-7_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-41768-0
Online ISBN: 978-3-030-41769-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)